- SPANNR
- Posts
- Issue #32
Issue #32
Issue #32
January 5, 2023 | Issue #32
Good evening. Welcome back to another issue of Spannr. Surprise, surprise, there have been a ton of noteworthy articles published by big outlets over the past couple of weeks at a time when health resolutions are a thing. From the New York Times, Wired, and National Geographic... to Inc., FT, The Times, and Smithsonian – it seems that everyone, in one way or another, had something to say about the fields of aging/longevity.Perhaps there's a reason why CB Insights just published a report claiming "Immortality-as-a-service" as a top 10 tech trend of 2023 :)Happy new year! We've got much to look forward to.In this week's newsletter:⏱️ AgeRate: A direct-to-consumer longevity startup📈 Index rebalance & Q4 2022 review✨ Business news & more
Longevity = Freedom
In the latest addition to our interview series, we sit down with Cole Kirschner, the visionary CEO and co-founder of AgeRate.In this interview, Cole shares the origin story of his direct-to-consumer longevity startup, which uses blood tests to reveal to consumers how well they are aging and give them the tools and knowledge they need to optimize their health and aging process.After learning that the company recently raised a $300,000 seed round, we reached out to Cole to learn more about what the AgeRate team is working on.Continue reading to learn more about Cole’s inspiring journey and the groundbreaking work of AgeRate.
Spannr's Longevity Stock Index Lost 8.49% In Q4 2022
The Spannr Longevity Stock Index was introduced in 2022 as the first index of its kind to provide real-time tracking of the entire public longevity market.In this report, we will review the index’s performance over the past few months and compare it to the overall market and relevant biotech ETFs.Additionally, we will discuss the best and worst performers from Q4 2022 and introduce the newly added index constituents following our quarterly rebalance, which occurred on January 2, 2022.
Geron Announces Positive Top-Line Results from IMerge Phase 3 Trial of Imetelstat in Lower Risk MDS
Hevolution Foundation Appoints William Greene, MD as Chief Investment Officer
Ocugen Announces Phase 3 Confirmatory Clinical Trial Agreement for NeoCart – an important next step for Ocugen’s regenerative cell therapy in orthopedics since announcing pipeline expansion in May 2022
Fate Therapeutics Announces Termination of Collaboration Agreement with Janssen, Pipeline Prioritization, Next-Generation Programs, and Key 2023 Initiatives
Curative Biotechnology Announces Completion of IND Enabling Reformulated Metformin HCL Eye Drop Study
Capsida makes $55M deal with Eli Lilly to develop gene therapies
Congress eliminates the need for animal testing of drugs (Methuselah Foundation)
Could getting rid of old cells turn back the clock on aging? (Knowable Magazine)
Scientists develop cell therapy engineered to kill and prevent brain cancer in advanced mouse model (The Harvard Gazette)
Cheating My Way to a Ketogenic Lifestyle (NEO.LIFE)
Study Suggest How Many Minutes of Exercise Per Day Could Help Increase Longevity (Inverse)
Visualizing Healthcare Spending & Life Expectancy, By Country (Visual Capitalist)
A New Treatment For Arthritis: Vagus-Nerve Stimulation (IEEE)
Meet the Neuralink Cofounder Who Left and Started a Competitor That's Now Rapidly Catching Up (Futurism)
8 Resolutions Longevity Experts Want You to Make This Year (Livestrong)
Top Life Sciences Startups to Watch in 2023 (BioSpace)
Is there really such a thing as brain food? (Buck Institute)
*Performance:
Latest Price: $109.5414d-Return: -2.57% Market Cap: $11.22b
*Spannr did not send an email on December 29th due to the holidays, therefore we are reporting 14-day returns.